Lead Product(s) : Ppi-1011
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mld's PPI-1011 Shows Positive Phase 1 Results as Synthetic Plasmalogen Precursor
Details : PPI-1011 is a synthetic plasmalogen precursor being developed as a treatment for diseases of plasmalogen deficiency, including Rhizomelic chondrodysplasia punctata (RCDP).
Product Name : PPI-1011
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 17, 2025
Lead Product(s) : Ppi-1011
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
